Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGIR | P43119 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411801 | 0.92 | LPAR1 (0.54) | LTB4R2LPAR1PTGDR2 | |
| SCHEMBL5395527 | 0.92 | LPAR1 (0.43) | LTB4R2PPARAPPARGLPAR1PTGDR2 | |
| SCHEMBL5402519 | 0.92 | PPARG (0.47) | LTB4R2PPARAPPARGLPAR1CYP2D6 | |
| SCHEMBL5414873 | 0.91 | LTB4R (0.45) | LTB4R2PPARGLPAR1CYP2D6PTGDR2 | |
| SCHEMBL5414300 | 0.91 | LTB4R2 (0.53) | LTB4R2LPAR1LTB4R | |
| SCHEMBL5409406 | 0.89 | LTB4R (0.48) | LTB4R2PPARAPPARGCYP2D6LTB4R | |
| SCHEMBL5398871 | 0.87 | LTB4R2 (0.56) | LTB4R2LPAR1PKM | |
| SCHEMBL5394549 | 0.87 | LPAR1 (0.54) | LTB4R2LPAR1 | |
| SCHEMBL5403994 | 0.86 | LPAR1 (0.50) | LTB4R2LPAR1 | |
| SCHEMBL5401488 | 0.86 | LPAR1 (0.50) | LTB4R2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | LTB4R2 329/4885PPARA 195/4885PPARG 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.